DE69131709T2 - Liposomen enthaltende impfstoffzusammensetzungen - Google Patents

Liposomen enthaltende impfstoffzusammensetzungen

Info

Publication number
DE69131709T2
DE69131709T2 DE69131709T DE69131709T DE69131709T2 DE 69131709 T2 DE69131709 T2 DE 69131709T2 DE 69131709 T DE69131709 T DE 69131709T DE 69131709 T DE69131709 T DE 69131709T DE 69131709 T2 DE69131709 T2 DE 69131709T2
Authority
DE
Germany
Prior art keywords
compositions containing
vaccine compositions
containing liposomes
liposome
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131709T
Other languages
English (en)
Other versions
DE69131709D1 (de
Inventor
Gail Barchfeld
Gary Ott
Nest Gary Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69131709D1 publication Critical patent/DE69131709D1/de
Application granted granted Critical
Publication of DE69131709T2 publication Critical patent/DE69131709T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69131709T 1990-06-29 1991-06-25 Liposomen enthaltende impfstoffzusammensetzungen Expired - Fee Related DE69131709T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54658590A 1990-06-29 1990-06-29
PCT/US1991/004532 WO1992000081A1 (en) 1990-06-29 1991-06-25 Vaccine compositions containing liposomes

Publications (2)

Publication Number Publication Date
DE69131709D1 DE69131709D1 (de) 1999-11-18
DE69131709T2 true DE69131709T2 (de) 2000-05-25

Family

ID=24181076

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131709T Expired - Fee Related DE69131709T2 (de) 1990-06-29 1991-06-25 Liposomen enthaltende impfstoffzusammensetzungen

Country Status (17)

Country Link
EP (1) EP0489153B1 (de)
JP (1) JP2502234B2 (de)
AT (1) ATE185486T1 (de)
AU (1) AU654824B2 (de)
BR (1) BR9106604A (de)
CA (1) CA2086094C (de)
DE (1) DE69131709T2 (de)
DK (1) DK0489153T3 (de)
ES (1) ES2138588T3 (de)
FI (1) FI925835A0 (de)
GR (1) GR3031528T3 (de)
HU (1) HU220136B (de)
IE (1) IE912286A1 (de)
NO (1) NO924858L (de)
OA (1) OA09800A (de)
PT (1) PT98156B (de)
WO (1) WO1992000081A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692149B1 (fr) * 1992-06-12 1995-06-09 Vacsyn France Sa Composition adjuvante de l'immunite humorale et a mediation cellulaire n'induisant pas de reponse vis-a-vis de determinants auto-antigeniques.
AU5420494A (en) * 1992-11-02 1994-05-24 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH09503396A (ja) * 1994-07-29 1997-04-08 インノジェネティクス・エヌ・ブイ 診断用及び治療用の精製ｃ型肝炎ウイルスエンベロープ蛋白
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
AU5978596A (en) * 1995-06-07 1996-12-30 U.S. Department Of The Army Liposomes containing human immunodeficiency virus glycoprote in and methods for use thereof
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
CA2314934C (en) 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
CA2689696C (en) * 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
ATE317267T1 (de) 2000-11-07 2006-02-15 Immunovaccine Technologies Inc Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
EP1415648B1 (de) * 2001-07-13 2006-11-22 NanoCarrier Co., Ltd. Lyophilisierende zusammensetzung von wirkstoff-verkapselnder polymer-mizelle und verfahren zu ihrer herstellung
KR20030097099A (ko) * 2002-06-19 2003-12-31 현대자동차주식회사 저압 주조를 위한 금형의 용탕 충진 속도 측정장치
WO2004060396A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
EP2197497B1 (de) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Verwendung von liposomen in einem träger mit einer kontinuierlichen hydrophoben phase zur abgabe von polynucleotiden in vivo
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
ES2530049T3 (es) * 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2840079C (en) * 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
BR112014007927B1 (pt) 2011-10-06 2021-04-13 Immunovaccine Technologies Inc Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS6137738A (ja) * 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン

Also Published As

Publication number Publication date
EP0489153A1 (de) 1992-06-10
HU220136B (hu) 2001-11-28
FI925835A (fi) 1992-12-22
OA09800A (en) 1994-04-15
JPH06504759A (ja) 1994-06-02
EP0489153A4 (en) 1993-04-21
AU654824B2 (en) 1994-11-24
HUT67055A (en) 1995-01-30
DE69131709D1 (de) 1999-11-18
AU8323091A (en) 1992-01-23
NO924858D0 (no) 1992-12-15
PT98156B (pt) 1998-12-31
HU9204136D0 (en) 1993-11-29
ES2138588T3 (es) 2000-01-16
DK0489153T3 (da) 2000-01-24
CA2086094A1 (en) 1991-12-30
JP2502234B2 (ja) 1996-05-29
PT98156A (pt) 1992-04-30
WO1992000081A1 (en) 1992-01-09
ATE185486T1 (de) 1999-10-15
EP0489153B1 (de) 1999-10-13
BR9106604A (pt) 1993-06-22
GR3031528T3 (en) 2000-01-31
IE912286A1 (en) 1992-01-01
NO924858L (no) 1993-02-25
FI925835A0 (fi) 1992-12-22
CA2086094C (en) 2000-05-30

Similar Documents

Publication Publication Date Title
DE69131709T2 (de) Liposomen enthaltende impfstoffzusammensetzungen
LU91486I2 (fr) Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
ATE95425T1 (de) Impfstofformulierung.
FI20011187A (fi) Antigeenin kanssa käytettäväksi tarkoitettuja koostumuksia
DK0382271T3 (da) Tocoler som adjuvanser i vacciner
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DE69533693D1 (de) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
DE69112634D1 (de) Immunogene komplexe, insbesondere iscoms.
ES2097840T3 (es) Adyuvante de vacuna que comprende un tetrapoliol.
GEP20053446B (en) Adjuvant Combination Formulations
CR6332A (es) Composiciones de liposomas inmunogenicos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee